Press Releases Immuneering Corporation

Equities

IMRX

US45254E1073

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
1.56 ^USD	-4.29%		0.00%	-78.78%

05-07	Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-09	Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates	05-07	GL
Immuneering Recognizes Melanoma Awareness Month	05-06	GL
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models	04-09	GL
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04-03	GL
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	03-27	GL
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	03-27	AQ
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI	03-20	AQ
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	03-14	GL
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	03-14	AQ
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	03-12	GL
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	03-12	AQ
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors	03-11	GL
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024	03-05	GL
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024	03-05	AQ
Immuneering to Participate in the Cowen 44th Annual Health Care Conference	03-04	GL
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	03-01	GL
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer	02-20	GL
Immuneering Announces Participation in February Investor Conferences	02-01	GL
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	12-12	GL
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	12-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immuneering Corporation

Equities

IMRX

US45254E1073

Press Releases

Filters